These brand lawsuits challenging generic introductions are still out there despite some reforms to stop them under earlier administrations. While the Glenmark challenge and introduction was clearly justified, the two parties "settled" the lawsuit and Glenmark agreed to delay a generic launch for five years but also got a huge "reverse compensation payment" when Merck agreed not to launch its own generic in the market when Glenmark was free to launch one under the agreement. This gave Glenmark huge market share and earnings. The insurers paid hundreds of millions more because of the deal. The scheme has also been subject to several class-action lawsuits and settlements.